Gene therapy breakthrough poised for massive FDA windfall

Current Price

$21.09

Unrealized P&L

+0.4%

Entry Zone

$20.58 – $21.86

Target

$52.00

+147.6% upside

Stop Loss

$18.50

Catalyst

FDA decision on SRP-9001 for limb-girdle muscular dystrophy expected by May 15, 2026· May 15, 2026

Time Horizon

4 weeks

Sarepta sits at an inflection point that the market has completely ignored. The FDA is expected to rule on SRP-9001 for limb-girdle muscular dystrophy by May 15, 2026, following accelerated approval pathway discussions. Clinical data from the Phase II study showed 12% improvement in North Star Ambulatory Assessment scores at 48 weeks, matching the efficacy threshold that secured Elevidys approval for Duchenne muscular dystrophy. The addressable patient population exceeds 15,000 in the US alone, with pricing expected to mirror Elevidys at $3.2 million annually. The current $2.2 billion market cap prices in zero value for this program despite Sarepta's proven gene therapy manufacturing and regulatory expertise. Wall Street has been distracted by Duchenne competition concerns, but LGMD represents a greenfield opportunity with no approved treatments. Management guided for commercial launch readiness by Q3 2026 if approved. Second catalyst emerges from the dystroglycanopathy program, where FDA granted Fast Track designation in March. This ultra-rare indication could command even higher pricing given the severe unmet need and tiny patient population under 2,000 globally. Key risks center on FDA requiring additional studies or safety concerns, though the agency's recent gene therapy approvals suggest regulatory momentum. Competition risk remains minimal given the complexity and cost of developing competing gene therapies. Current 7.1x forward PE multiple assumes no pipeline value, creating asymmetric opportunity. Stock traded above $140 in 2022 before pipeline delays; successful approval could drive 150%+ rerating toward $50+ as commercial potential becomes clear.